<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157467</url>
  </required_header>
  <id_info>
    <org_study_id>206293</org_study_id>
    <secondary_id>AI468-041</secondary_id>
    <nct_id>NCT02157467</nct_id>
  </id_info>
  <brief_title>Study of Combined Oral Contraceptive Effects in Female Subjects</brief_title>
  <official_title>The Effect of Coadministration of BMS-955176 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of BMS-955176 on the pharmacokinetics of
      coadministered oral contraceptives.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2014</start_date>
  <completion_date type="Actual">August 25, 2014</completion_date>
  <primary_completion_date type="Actual">August 25, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serial blood samples for plasma Ethinyl Estradiol and Norelgestromin determination</measure>
    <time_frame>Before dosing (0 hour) through 24 hours after administration on Days 21 and 49</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum progesterone measurements</measure>
    <time_frame>Day 14, 21, 35, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough blood samples collected for BMS-955716</measure>
    <time_frame>Days 48, 49, 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.</measure>
    <time_frame>Two to three months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Arm 1: NGMN/EE + BMS-955176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28
Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-955176</intervention_name>
    <arm_group_label>Arm 1: NGMN/EE + BMS-955176</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho Cyclen</intervention_name>
    <arm_group_label>Arm 1: NGMN/EE + BMS-955176</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Written Informed Consent a) The signed informed consent form

          2. Target population

               -  a) Healthy female subjects as determined by no clinically significant deviation
                  from normal in medical history, physical examination findings, vital sign
                  measurements, 12-lead ECG measurements, physical measurements, and clinical
                  laboratory test results

               -  b) Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive, at screening and Day
                  -1. BMI = weight (kg)/[height (m)]2

               -  c) Weight greater than or equal to 45 kg

               -  d) Subject Reenrollment: This study permits the reenrollment of a subject that
                  has discontinued study as a pretreatment failure (ie, has not been treated). If
                  reenrolled, the subject must be reconsented

          3. Age and Reproductive Status

               -  a) Women, 18 to 40 years of age, inclusive

               -  b) Women of childbearing potential (WOCBP) with intact ovarian function as
                  determined by medical history and history of regular menstrual cycles, and who
                  have been on a stable regimen of Ortho Cyclen for at least 2 consecutive months
                  without evidence of breakthrough bleeding or spotting, or subjects who have been
                  using a stable regimen of another combination oral contraceptive containing EE
                  for at least two months prior to dosing on Day 1 of Cycle 1 and willing to switch
                  to Ortho Cyclen for the total duration of the study (approximately 78 days)

               -  c) Women must have a negative serum or urine pregnancy test (minimum sensitivity
                  25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours
                  prior to dosing on Day 1 of Cycle 1

               -  d) Women must not be breastfeeding

        Exclusion Criteria:

        Medical History and Concurrent Diseases

          -  a) Any significant acute or chronic medical illness

          -  b) History of biliary disorders, including Gilbert's disease or Dubin-Johnson disease

          -  c) Current or recent (within 3 months of dosing on Day 1 of Cycle 1) gastrointestinal
             disease

          -  d) Any major surgery within 4 weeks of dosing on Day 1 of Cycle 1

          -  e) Any gastrointestinal surgery (including cholecystectomy) that could impact upon the
             absorption of study drug

          -  f) Donation of &gt; 400 mL to a blood bank or in a clinical study (except a screening
             visit) within 8 weeks of dosing on Day 1 of Cycle 1

          -  g) Blood transfusion within 4 weeks of dosing on Day 1 of Cycle 1

          -  h) Inability to tolerate oral medication

          -  i) Inability to be venipunctured and/or tolerate venous access

          -  j) Smokers (those who currently smoke, as well as those who have stopped smoking less
             than 6 months prior to dosing on Day 1 of Cycle 1)

          -  k) Recent (within 6 months of dosing on Day 1 of Cycle 1) drug or alcohol abuse as
             defined in Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM
             IV), Diagnostic Criteria for Drug and Alcohol Abuse

          -  l) Any other sound medical, psychiatric, and/or social reason as determined by the
             investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viiv Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

